Investigating how a specific receptor affects cholesterol levels in the liver
Role of Retinoid X Receptor Alpha in regulating PCSK9 transcription in the liver
['FUNDING_R01'] · NYU LONG ISLAND SCHOOL OF MEDICINE · NIH-11038045
This study is looking at how a specific protein called RXRα affects cholesterol production in the liver, especially for people with nonalcoholic fatty liver disease (NAFLD), to help find new ways to manage cholesterol levels and lower the risk of heart problems.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NYU LONG ISLAND SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (MINEOLA, UNITED STATES) |
| Trial ID | NIH-11038045 on ClinicalTrials.gov |
What this research studies
This research explores the role of Retinoid X Receptor Alpha (RXRα) in regulating the production of PCSK9, a protein that influences cholesterol levels in the liver. By studying how RXRα interacts with other nuclear receptors, the research aims to uncover mechanisms that lead to increased cholesterol and LDL-C levels, particularly in patients with nonalcoholic fatty liver disease (NAFLD). The approach includes using animal models to observe the effects of RXRα depletion and overexpression on cholesterol metabolism. The findings could provide insights into new treatment strategies for managing cholesterol levels and reducing cardiovascular disease risk.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with nonalcoholic fatty liver disease (NAFLD) who are at risk for elevated cholesterol and cardiovascular diseases.
Not a fit: Patients without liver disease or those who do not have issues related to cholesterol metabolism may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively lower cholesterol levels and reduce the risk of cardiovascular diseases.
How similar studies have performed: Previous research has shown promising results in targeting PCSK9 for cholesterol management, indicating that this approach has potential based on established findings.
Where this research is happening
MINEOLA, UNITED STATES
- NYU LONG ISLAND SCHOOL OF MEDICINE — MINEOLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MIAO, QING — NYU LONG ISLAND SCHOOL OF MEDICINE
- Study coordinator: MIAO, QING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Atherosclerotic Cardiovascular Disease, atherosclerotic disease, atherosclerotic vascular disease